6 OncoGenex Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $OGXI | NASDAQ:OGXI | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 5 Buy Rating(s), 1 Strong Buy Rating(s)Consensus Rating:Buy (Score: 3.17)Consensus Price Target: $21.15 (52.71% upside) Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/27/2014CRT CapitalInitiated CoverageBuy$20.00View 11/8/2013Stifel NicolausLower Price TargetBuy$26.00 -> $21.00View 10/28/2013Needham & CompanyUpgradeBuy -> Strong-Buy$20.00 -> $30.00View 8/9/2013Stifel NicolausLower Price TargetBuy$30.00 -> $26.00View 7/3/2013ZacksUpgradeNeutral -> Outperform$11.90View 5/6/2013RBC CapitalBoost Price TargetOutperform$17.00 -> $19.00View 5/3/2013Bloom BurtonBoost Price TargetBuy$20.00 -> $25.00View 3/8/2013Bloom BurtonBoost Price Target$18.00 -> $20.00View 8/3/2012Needham & CompanyReiterated RatingBuyView 6/18/2012Needham & CompanyInitiated CoverageBuy$30.00View 5/4/2012Bloom BurtonLower Price TargetBuy$19.00 -> $18.00View 3/27/2012Leerink SwannInitiated CoverageOutperformView (Data available from 3/10/2012 forward) Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View 8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View 3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View 8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View (Data available from 1/1/2013 forward) About OncoGenex Pharmaceuticals OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company's product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models. Headlines: (3/6) OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% (2/11) OncoGenex Pharmaceuticals (OGXI) Jumps: Stock Rises 5.8% (2/25) OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014 (2/11) OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate ... (2/13) Pipeline Progress at OncoGenex (2/28) RDInvesting Provides Investors with Free In-Depth Equity Reports on BIOS, DYAX, NKTR and OGXI Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: OGXI CUSIP: 68230A10 Key Metrics: Previous Close: $12.7250 Day Moving Average: $11.2971200 Day Moving Average: $9.1406 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $203.7MCurrent Quarter EPS Consensus Estimate: $-2.38 EPS Additional Links: View OGXI on Google FinanceView OGXI on Yahoo FinanceView OGXI's Company Profile on ReutersSearch for OncoGenex Pharmaceuticals Inc. on Google OncoGenex Pharmaceuticals (NASDAQ:OGXI) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.